Introduction
============

Tuberculosis (TB) is a global health problem, and 10.0 million new cases were reported and an estimated 1.3 million deaths occurred due to TB in 2017.[@b1-tcrm-15-377] To facilitate the elimination of TB, numerous evidence-based guidelines have been developed for the standard management of TB. However, no standard management protocol has been developed for patients with tuberculous destroyed lung (TDL), possibly because studies targeting TDL (especially randomized controlled trials or observational studies) have rarely been performed and no medications targeting TDL have been developed. Even TB that was treated many years ago, may cause destruction of the lung, which can last for long period time after initial diagnosis or treatment of TB.[@b2-tcrm-15-377] The impairment in lung function can cause airflow limitation,[@b3-tcrm-15-377]--[@b5-tcrm-15-377] which might affect the clinical outcome.[@b6-tcrm-15-377] However, the prevalence, clinical manifestations, and optimal treatment of patients with TDL, as well as airflow limitation in these patients, have not been well investigated.

Despite the lack of standard therapy in patients with TDL, inhaler therapies such as inhaled long-acting muscarinic antagonist (LAMA) or corticosteroids/long-acting beta-2 agonist (ICS/LABA), are often used in these patients.[@b7-tcrm-15-377] Yum et al[@b8-tcrm-15-377] found that inhaled tiotropium might improve lung function in patients with TDL, and Kim et al[@b9-tcrm-15-377] recently showed that inhaled indacaterol improved lung function and symptom control in patients with TDL. However, these previous studies were performed using a short-term period of \~2 months; therefore, long-term outcomes, such as mortality, could not be evaluated. In addition, these studies included patients without airflow limitation, so the efficacy of inhaler therapies might have been affected.

Therefore, the current study aimed to investigate clinical characteristics and the effect of inhaler therapy on mortality in patients with TDL and airflow limitation in South Korea, a country with an intermediate TB burden.

Study population and methods
============================

Study design and populations
----------------------------

We identified a total of 1,725 patients diagnosed with TDL between January 2000 and December 2014 from the electronic medical records at Asan Medical Center, a tertiary referral hospital, in South Korea. In this study, TDL is defined as parenchymal damage on chest radiograph due to sequelae from past TB, and the airflow limitation is defined as FEV~1~/FVC \<70%. Among the 1,725 patients, 500 patients who had been followed up for \<360 days were excluded from this study in order to evaluate the long-term effect of inhaler therapy on mortality; in addition, 542 patients who had no airflow limitation at baseline pulmonary function test were also excluded from this study. Subsequently, the included patients were classified into the following groups based on the types of inhaler therapy that patients received: LAMA group and non-LAMA group or ICS/LABA group and non-ICS/LABA group. The LAMA group comprised patients who had been prescribed the tiotropium inhaler for ≥360 days during the follow-up period to investigate the effect in a relatively adherent group over a period of time; the non-LAMA group included patients who never had been prescribed tiotropium inhaler and those who had been prescribed the inhaler for \<360 days during the follow-up period. In addition, the ICS/LABA group included patients who had been prescribed the fluticasone propionate/salmeterol or budesonide/formoterol inhaler for ≥360 days during the follow-up period, and the non-ICS/LABA group comprised patients who never had been prescribed the fluticasone propionate/salmeterol or budesonide/formoterol inhaler and those who had been prescribed the inhaler for \<360 days during the follow-up period. The study flow chart is shown in [Figure 1](#f1-tcrm-15-377){ref-type="fig"}. The study protocol was approved by the Institutional Review Board of Asan Medical Center (2016--1028). The patient data were anonymized or maintained with confidentiality, in accordance with the Declaration of Helsinki. Because this study comprised a retrospective review of medical records, written informed consent was waived.

Data collection
---------------

Data regarding age, gender, body mass index (BMI), smoking history, mMRC score,[@b10-tcrm-15-377] comorbidity measured by the Charlson Comorbidity Index (CCI),[@b11-tcrm-15-377] pulmonary function tests, prescription of LAMA or ICS/LABA inhaler, and usage of home oxygen were collected from electronic medical records. Pulmonary functions were measured according to American Thoracic Society recommendations, and the results are expressed as percentages of normal predicted values.[@b12-tcrm-15-377] To evaluate the severity of TDL on the posteroanterior chest radiograph, six regions of the lung (ie, upper, middle, and lower regions of the right and left lungs) were semi-quantified with a total severity score of 0--6.[@b7-tcrm-15-377] Clinical follow-up courses, including mortality of the patients until December 2016, were obtained from the data of the Korean national health insurance, in addition to the electronic medical records.

Statistical analysis
--------------------

Data collected from the inhaler therapy and non-inhaler therapy groups were compared using Student's *t*-test or the Mann--Whitney U test for continuous variables and the chi-squared test or Fisher's exact test for categorical variables. All *P*-values were two-tailed, with statistical significance set at *P*\<0.05. Risk factors for mortality were analyzed with Cox proportional hazards models. Variables with a *P*-value \<0.20 in the univariate analysis were used in the multivariate analysis. To avoid bias from the retrospective design in this cohort study, we performed propensity score matching to reduce potential confounding by non-random assignment or unbalanced covariates between LAMA and non-LAMA groups. The propensity score was calculated using logistic regression analysis with the following covariates: age, gender, BMI, smoking history, mMRC dyspnea score, CCI, concomitant asthma and COPD diagnosis, ICS/LABA inhaler usage over 360 days, pulmonary function tests, X-ray severity, and home oxygen usage. We compared the matched group using paired *t*-test or the paired Wilcoxon test (continuous variables) and the McNemar test (categorical data). The Kaplan--Meier survival analysis and log rank test were used to evaluate differences in mortality. All statistical analyses were performed using R software 3.5.1 version (R Foundation for Statistical Computing, Vienna, Austria) and SPSS 22.0 software (IBM Corporation, Armonk, NY, USA).

Results
=======

Patient characteristics
-----------------------

Among 683 patients with TDL and airflow limitation, 177 patients (25.9%) received LAMA inhaler treatment over 360 days (LAMA group) and 171 patients (25.0%) received ICS/LABA inhaler treatment over 360 days (ICS/LABA group). Patients in the LAMA group appeared to have worse baseline characteristics than did those in the non-LAMA group ([Table 1](#t1-tcrm-15-377){ref-type="table"}). Patients in the LAMA group were older (63.9 vs 61.3 years, *P*=0.004), had higher mMRC dyspnea scale, and proportion of concomitant asthma (19.8% vs 10.9%, *P*=0.003) than those in the non-LAMA group. In addition, patients were more frequently prescribed ICS/LABA inhaler in the LAMA group than in the non-LAMA group (18.8% vs 2.9%, *P*\<0.001). Baseline pulmonary functions were lower in the LAMA group than in the non-LAMA group (mean FEV~1~: 40.7% vs 54.1% predicted, *P*\<0.001), but X-ray severity (3.3 vs 2.9, *P*\<0.001), the proportion of respiratory admission within 2 years (16.9% vs 9.3%, *P*=0.006), and long-term oxygen therapy (16.9% vs 5.7%, *P*\<0.001) were higher in the LAMA group than in the non-LAMA group.

Patients in the ICS/LABA group also had worse baseline characteristics than non-ICS/LABA group ([Table 2](#t2-tcrm-15-377){ref-type="table"}). The mMRC dyspnea scale score, and the proportion of concomitant asthma (30.4% vs 7.4%, *P*\<0.001), were higher in the ICS/LABA group than in the non-ICS/LABA group. In addition, patients were prescribed LAMA more frequently in the ICS/LABA group than in the non-ICS/LABA group (62.6% vs 13.7%, *P*\<0.001). Baseline pulmonary functions were lower in the ICS/LABA group (mean FEV~1~: 40.2% vs 54.1% predicted, *P*\<0.001), whereas X-ray severity (3.3 vs 2.9, *P*\<0.001), and the proportion of long-term oxygen therapy (18.1% vs 5.5%, *P*\<0.001) were higher in the ICS/LABA group than in the non-ICS/LABA group.

Risk factors for mortality in patients with TDL and airflow limitation
----------------------------------------------------------------------

During the median follow-up period of 1,566 days, 73 (10.7%) patients died. Univariate Cox proportional hazards modeling revealed that older age, male gender, lower BMI, ever smoker, higher CCI, lower FEV~1~, severe chest X-ray findings, and long-term oxygen usage were related to higher mortality. Multivariate Cox proportional hazards model analysis showed that age (HR, 1.059; 95% CI, 1.032--1.087; *P*\<0.001), BMI (HR, 0.892; 95% CI, 0.826--0.964; *P*=0.004), CCI (HR, 1.495; 95% CI, 1.315--1.700; *P*\<0.001), and X-ray severity (HR, 1.244; 95% CI, 1.004--1.541; *P*=0.045) were significant independent risk factors for mortality. LAMA inhaler usage was not a significant risk factor for mortality in the univariate analysis, but was associated with lower risk of mortality in the multivariate analysis (HR, 0.405; 95% CI, 0.211--0.776; *P*=0.006, [Table 3](#t3-tcrm-15-377){ref-type="table"}). However, ICS/LABA inhaler usage was not a significant risk factor for mortality in both univariate and multivariate analysis.

Propensity score matching between LAMA and non-LAMA groups
----------------------------------------------------------

Because baseline pulmonary function and other baseline characteristics in addition to ICS/LABA inhaler usage were significantly different between LAMA and non-LAMA, patients were matched based on the logit of the propensity score. After propensity score matching, 121 patients were selected from each group. Furthermore, we performed additional propensity score matching after patients with ICS/LABA inhaler usage over 360 days were excluded; 64 patients were selected from each of the LAMA and non-LAMA groups. Baseline characteristics were not different between LAMA and non-LAMA groups after the two propensity score matchings analyses ([Table 4](#t4-tcrm-15-377){ref-type="table"}).

Comparison of mortality between LAMA and non-LAMA groups before and after propensity score matching
---------------------------------------------------------------------------------------------------

Kaplan--Meier survival analysis showed no significant differences between LAMA and non-LAMA groups before propensity score matching ([Figure 2A](#f2-tcrm-15-377){ref-type="fig"}, *P*=0.115). However, after propensity score matching, the survival period in the LAMA group was significantly longer than that in the non-LAMA group ([Figure 2B](#f2-tcrm-15-377){ref-type="fig"}, *P*=0.002). The results were similar even after patients with ICS/LABA usage were excluded ([Figure 2C](#f2-tcrm-15-377){ref-type="fig"}, *P*=0.043). Three sets of analyses (before propensity score matching, after propensity score matching including patients with ICS/LABA usage, and after propensity score matching excluding patients with ICS/LABA usage) revealed that the follow-up period did not significantly differ between the LAMA and the non-LAMA groups ([Table S1](#SD2-tcrm-15-377){ref-type="supplementary-material"}). Similar with Kaplan--Meier survival analysis, 5-year mortality rate was lower in the LAMA group than in the non-LAMA group after propensity score matching including patients with ICS/LABA usage (2.5 vs 9.1%, *P*=0.057) and excluding patients with ICS/LABA usage (3.1 vs 14.1%, *P*=0.039).

Discussion
==========

Our current study showed that the LAMA inhaler therapy might reduce mortality in patients with TDL and airflow limitation. Although LAMA inhaler was prescribed more often for patients with older age, more symptoms, and reduced lung function, the patients in the LAMA group showed lower overall mortality than patients in the non-LAMA group, after adjusting for unbalanced covariates. To the best of our knowledge, none of the prior studies investigated the role of inhaler therapy in the mortality of patients with TDL and airflow limitation.

Although there is no consensus standard treatment for patients with TDL and airflow limitation, inhaler therapy, such as inhaled LAMA or ICS/LABA, is often applied in real practice.[@b7-tcrm-15-377] LAMA inhaler has been widely used in COPD patients.[@b13-tcrm-15-377] However, there are few data regarding the use of inhaler therapy in patients with TDL. A recent study found that among 29 patients with TDL, 20 patients (72%) exhibited an increase of \>10% in FEV~1~ over baseline after 2 months of tiotropium treatment,[@b8-tcrm-15-377] and the results suggested that relaxation of the bronchial smooth muscle and/or reduction of airway secretion by tiotropium might improve pulmonary function. In our current study, we found that 177 patients (25.9%) were prescribed LAMA inhaler for over 360 days. Importantly, our study demonstrated that the prognosis of patients was better in the LAMA group than in the non-LAMA group, even after adjusting unbalanced covariates between two group and excluding patients with using ICS/LABA usage. These findings reinforce the importance of LAMA inhaler treatment for patients with TDL and airflow limitation.

Although the ICS/LABA inhaler has been used as one of the treatment options for patients with COPD,[@b14-tcrm-15-377] the LAMA inhaler alone or in the combination with the LABA inhaler is the preferred therapeutic option for patients with COPD because of its great efficacy and low adverse events, such as pneumonia.[@b15-tcrm-15-377],[@b16-tcrm-15-377] Previous studies reported an effect of inhaler on pulmonary function in patients with TDL. Kim et al[@b9-tcrm-15-377] reported that indacaterol group had improved FEV~1~ and transition dyspnea index compared with the placebo group in 119 patients with TDL and moderate to severe airflow limitation. In addition, Rhee et al,[@b7-tcrm-15-377] in 35 patients with TDL, reported that both LAMA and ICS/LABA inhaler usage significantly increased the FEV~1~ (respectively 0.14 and 0.28 L) compared to those of patients who did not use medication (0.01 L).[@b7-tcrm-15-377] However, no previous study has investigated the role of inhaler therapy on mortality in patients with TDL. In the current study, while the LAMA inhaler usage was favorable prognostic factor, the ICS/LABA inhaler usage was not associated with prognosis in patients with TDL and airflow limitation. The reason for this result is unclear, and one possible explanation is that our study included small number of patients with asthma or bronchodilator response. In fact, 13.2% of patients had concomitant asthma and 7.2% of patients with available post-bronchodilator pulmonary function test had a bronchodilator response in the current study. Notably, growing evidences indicate that ICS might increase the risk of pneumonia or reactivation of TB.[@b17-tcrm-15-377]--[@b19-tcrm-15-377] Therefore, ICS/LABA inhaler should only be prescribed for a selected group of patients with TDL.

TB can cause the progressive and extensive destruction of lung parenchyma, and the damage may induce chronic airflow obstruction (with ranges of 30%--80%).[@b6-tcrm-15-377],[@b20-tcrm-15-377]--[@b23-tcrm-15-377] Furthermore, Plit et al[@b24-tcrm-15-377] showed that a substantial proportion of patients with TB had impaired lung function, even after successful TB treatment. The prevalence of airflow limitation in patients with TDL was 55.8% in our study, which is comparable with that in previous studies. A few studies have shown that airflow limitation might affect the clinical course of patients with TDL. Lee et al[@b5-tcrm-15-377] found that patients with airflow limitation and TDL had higher airflow resistance and lower positive bronchodilator response rates compared with COPD patients. Kim et al[@b6-tcrm-15-377] showed that airflow limitation was an independent risk factor for acute exacerbation (HR 1.634, *P*=0.044) in 158 patients with TDL. However, treatment information that could affect prognosis was not considered in that study. In addition, Rhee et al[@b7-tcrm-15-377] showed that the numbers of exacerbations did not differ in TDL patients with and without airflow limitation, although patients with airflow limitation had lower FEV~1~, these patients used LAMA or ICS/LABA more frequently than did those without airflow limitation in that study. In our current study, patients with airflow limitation tended to have worse prognosis than did those without airflow limitation group, with marginal significance (*P*-value =0.067) ([Figure S1](#SD1-tcrm-15-377){ref-type="supplementary-material"}). Although patients with airflow limitation had worse baseline characteristics than those without airflow limitation, inhaler therapy was prescribed more frequently in patients with airflow limitation than in those without airflow limitation ([Table S2](#SD3-tcrm-15-377){ref-type="supplementary-material"}). These findings suggest that inhaler treatment might be associated with favorable prognosis in patients with TDL.

Beside LAMA inhaler usage, older age, lower BMI, and higher CCI were associated with higher mortality. These variables are relatively well known as predictors of poor prognosis in patients with COPD.[@b25-tcrm-15-377]--[@b27-tcrm-15-377] In addition, the present study found that higher X-ray severity was associated with poor prognosis. The findings in the present study are supported by those in previous studies. Ryu et al[@b28-tcrm-15-377] found that the extent of the destroyed lung parenchyma was only independent prognostic factor for mortality in 169 patients with TDL (HR 3.52, *P*=0.004). Therefore, patients with severe lung destruction should be monitored carefully and treated actively.

In our study, subjects were followed up for a relatively long period of time (median, 1,566 days). Although the follow-up duration for the LAMA group was not different for the non-LAMA group after propensity score-matching analysis, the 5-year mortality rate was lower in the LAMA group than in the non-LAMA group. In addition, \~50% of patients in the LAMA group had a medication possession ratio (MPR) ≥80%, and these patients were classified as the "adherent group" in many previous studies.[@b29-tcrm-15-377]--[@b32-tcrm-15-377] Collectively, these results indicate that LAMA inhaler therapy might be effective in reducing mortality in patients with TDL and airflow limitation.

This study has several limitations. First, our study was retrospective in nature. However, this study included a large number of patients with few missing data. In addition, we used a statistical method (propensity score analysis) to reduce confounding factors. Second, the treatment duration during the follow-up period was variable in the LAMA group. Although the LAMA group only included patients who used the LAMA inhaler for \>360 days to enable evaluation of the long-term effect, 13 patients (7.3% in the total LAMA group) were prescribed the LAMA inhaler for \<30% of the total follow-up period. These patients might have interfered with the accurate results in our study. Moreover, after propensity score matching, among patients in the non-LAMA group, 46 patients (38.0%) were prescribed the LAMA inhaler \<1 year (median treatment duration: 100 days). However, none of these patients had died, which might have some effect on the results of this study. Finally, our study included patients at a single referral center in South Korea. Thus, external validation studies with other populations of patients with TDL and airflow limitation are needed. On the other hand, our study has advantages in data collection. We collected survival information of all patients by using the national health insurance database in South Korea, which makes it possible to trace the death of patients. Since South Korea has a mandatory universal health insurance system for the entire Korean population, it provides an accurate and useful research source.[@b33-tcrm-15-377],[@b34-tcrm-15-377]

Conclusions
===========

The current study findings suggest that LAMA inhaler therapy might be associated with favorable prognosis in patients with TDL and airflow limitation. Therefore, LAMA inhaler therapy can be considered as a reasonable treatment option for these patients.

Ethics approval
===============

The study protocol was approved by the Institutional Review Board of Asan Medical Center (2016-1028). Because this study comprised a retrospective review of medical records, written informed consent was waived.

Supplementary material
======================

###### 

Comparison of Kaplan--Meier survival curves between patients with airflow limitation and without airflow limitation.

**Note:** *P*-value from Log rank test.

###### 

Clinical course and medication history of patients in LAMA group and non-LAMA group

                                                     Before propensity score matching   After propensity score matching (including patients with ICS/LABA usage)   After propensity score matching (excluding patients with ICS/LABA usage)                                                                                                                                             
  -------------------------------------------------- ---------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------ -------------------------------------------------------- --------- ---------------------- ---------------------- ----------
                                                                                                                                                                                                                                                                                                                                                                                        
  Number of patients                                                                                                                                                                                                                                                                                                                                                                    
  Median follow-up duration, days                    1,687 \[1,048--2,352\]             1,517 \[863--2,479\]                                                       0.462                                                                      1,747 \[1,085--2,446\]   1,498 \[973--2,465\]                                     0.341     1,603 \[928--2,424\]   1,052 \[622--1,930\]   0.011
  Mean follow-up duration, days                      1,794.4±944.6                      1,918.9±1,384.6                                                            0.186                                                                      1,843.7±911.5            1,897.3±1,311.4                                          0.712     1,770.9±1,015.3        1,483.5 ±1,284.5       0.163
  Death within 5-year                                7 (4.0)                            36 (7.1)                                                                   0.136                                                                      3 (2.5)                  11 (9.1)                                                 0.028     2 (3.1)                9 (14.1)               0.027
  Median LAMA prescription duration, days (median)   940 \[600--1,455\]                 90 \[30--180\]                                                             \<0.001                                                                    1,010 \[605--1,435\]     0 \[0--50\]                                              \<0.001   845 \[490--1,275\]     0 \[0--48\]            \<0.001
  Mean LAMA prescription duration, days (mean)       1,047.3±494.4                      114.6±91.9                                                                 \<0.001                                                                    1,046.2±486.3            48.8±88.8                                                \<0.001   901.3±39.7             454.3± 73.3            \<0.001
  MPR ≥ 80%                                          97 (54.8)                          1 (0.7)[\*](#tfn12-tcrm-15-377){ref-type="table-fn"}                       \<0.001                                                                    59 (48.8)                1 (2.2)[\*\*](#tfn13-tcrm-15-377){ref-type="table-fn"}   \<0.001   30 (46.9)              0                      \<0.001
  MPR \< 30%                                         13 (7.3)                           134 (90.0)                                                                 \<0.001                                                                    9 (7.4)                  41 (89.1)                                                \<0.001   7 (10.9)               18 (75.0)              \< 0.001

**Notes:** Data are presented as median \[interquartile range\], mean ± standard deviation or number of patients (%).

Among non-LAMA group before propensity score matching, 149 patients received LAMA inhaler \<360 days. One patient received LAMA during 320 days (total follow-up period: 395 days).

Among non-LAMA group after propensity score matching (including patients with ICS/LABA usage), 46 patients received LAMA inhaler \<360 days. One patient received LAMA during 320 days (total follow-up period: 395 days).

Among non-LAMA group after propensity score matching (excluding patients with ICS/LABA usage), 24 patients received LAMA inhaler \<360 days.

**Abbreviations:** LAMA, long-acting muscarinic antagonist; ICS/LABA, inhaled corticosteroid/long-acting beta-2 agonist; MPR, medication possession ratio.

###### 

Baseline characteristics of patients in with or without airflow limitation groups

                                          With airflow limitation group   Without airflow limitation group   *P*-value
  --------------------------------------- ------------------------------- ---------------------------------- -----------
                                                                                                             
  Number of patients                      683 (55.8)                      542 (44.2)                         
  Age, years                              62.0±11.2                       56.4±13.5                          \<0.001
  Male gender                             471 (69.0)                      300 (55.4)                         \<0.001
  Body mass index, kg/m^2^                21.9±3.4                        21.5±3.6                           0.032
  Ever smoker                             404 (59.2)                      246 (45.4)                         \<0.001
  mMRC dyspnea scale                                                                                         \<0.001
   −0                                     223 (32.8)                      333 (61.4)                         
   −1                                     235 (34.6)                      112 (20.7)                         
   −2                                     124 (18.2)                      66 (12.2)                          
   −3                                     69 (10.1)                       23 (4.2)                           
   −4                                     29 (4.3)                        8 (1.5)                            
  Charlson Comorbidity Index              1.5±1.4                         1.0±1.3                            \<0.001
  Concomitant asthma                      90 (13.2)                       15 (2.6)                           \<0.001
  LAMA usage over 360 days                171 (25.0)                      23 (4.2)                           \<0.001
  ICS/LABA usage over 360 days            177 (25.9)                      31 (5.7)                           \<0.001
  Pulmonary function tests                                                                                   
   FEV~1~, % predicted                    50.6±19.5                       78.2±24.9                          \<0.001
   FVC, % predicted                       69.0±18.9                       73.9±23.2                          \<0.001
   FEV~1~/FVC ratio, %                    53.1±11.4                       80.5±0.08                          \<0.001
   DLco, % predicted                      67.8±21.6                       75.7±26.4                          \<0.001
   Respiratory admission within 2 years   77 (11.3)                       67 (12.4)                          0.557
   X-ray severity (0 to 6)                3.0±1.3                         2.3±1.5                            \< 0.001
   Long-term oxygen therapy               59 (8.6)                        31 (5.7)                           0.052

**Notes:** Data are presented as mean ± standard deviation or number of patients (%), unless otherwise indicated. Airflow limitation group was defined as patients who had FEV~1~/FVC \<70%.

**Abbreviations:** LAMA, long-acting muscarinic antagonist; ICS/LABA, inhaled corticosteroid/long-acting beta-2 agonist; DLco, diffusing capacity for carbon monoxide.
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**Abbreviation:** LAMA, long-acting muscarinic antagonist.](tcrm-15-377Fig1){#f1-tcrm-15-377}

![Comparison of Kaplan--Meier survival curves between LAMA and non-LAMA groups.\
**Notes:** (**A**) Before propensity score matching, (**B**) after propensity score matching, including patients with inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) usage, (**C**) after propensity score matching excluding patients with ICS/LABA usage. *P*-value from log rank test.\
**Abbreviation:** ICS/LABA, inhaled corticosteroid/long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist.](tcrm-15-377Fig2){#f2-tcrm-15-377}

###### 

Baseline characteristics of patients with airflow limitation according to LAMA usage over 360 days

                                          LAMA group[\*](#tfn2-tcrm-15-377){ref-type="table-fn"}   Non-LAMA group   *P*-value
  --------------------------------------- -------------------------------------------------------- ---------------- -----------
  Number of patients                      177 (25.9)                                               506 (74.1)       
  Age, years                              63.9±10.0                                                61.3±11.5        0.004
  Male gender                             132 (74.6)                                               339 (67.0)       0.061
  Body mass index, kg/m^2^                21.7±3.4                                                 22.0±3.4         0.272
  Ever smoker                             113 (63.8)                                               291 (57.5)       0.140
  mMRC dyspnea scale                                                                                                \<0.001
   −0                                     27 (15.3)                                                196 (38.9)       
   −1                                     69 (39.2)                                                166 (32.9)       
   −2                                     44 (25.0)                                                80 (15.9)        
   −3                                     24 (13.6)                                                45 (8.9)         
   −4                                     12 (6.8)                                                 17 (3.4)         
  Charlson Comorbidity Index              1.4±1.1                                                  1.5±1.4          0.496
  Concomitant asthma                      35 (19.8)                                                55 (10.9)        0.003
  ICS/LABA usage over 360 days            177 (18.8)                                               23 (2.9)         \<0.001
  Pulmonary function tests                                                                                          
   FEV~1~, % predicted                    40.7±13.0                                                54.1±20.2        \<0.001
   FVC, % predicted                       63.1±16.0                                                71.1±19.4        \<0.001
   FEV~1~/FVC ratio, %                    48.0±11.1                                                54.9±10.9        \<0.001
   DLco, % predicted                      56.7±22.1                                                71.5±20.2        \<0.001
   Respiratory admission within 2 years   30 (16.9)                                                47 (9.3)         0.006
   X-ray severity (0--6)                  3.3±1.3                                                  2.9±1.3          \<0.001
   Long-term oxygen therapy               30 (16.9)                                                29 (5.7)         \<0.001

**Notes:** Data are presented as mean ± SD or number of patients (%), unless otherwise indicated.

LAMA group included patients who were prescribed the tiotropium inhaler for ≥360 days during the follow-up period.

**Abbreviations:** DLco, diffusing capacity for carbon monoxide; ICS/LABA, inhaled corticosteroid/long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist.

###### 

Baseline characteristics of patients with airflow limitation according to ICS/LABA usage over 360 days

                                          ICS/LABA group[\*](#tfn5-tcrm-15-377){ref-type="table-fn"}   Non-ICS/LABA group   *P*-value
  --------------------------------------- ------------------------------------------------------------ -------------------- -----------
  Number of patients                      171 (25.0)                                                   512 (75.0)           
  Age (years)                             61.9±10.8                                                    62.0±11.4            0.930
  Male gender                             119 (69.6)                                                   352 (68.8)           0.837
  Body mass index, kg/m^2^                21.9±3.6                                                     21.9±3.4             0.969
  Ever smoker                             107 (62.6)                                                   297 (58.0)           0.293
  mMRC dyspnea scale                                                                                                        \<0.001
   −0                                     22 (12.9)                                                    201 (39.4)           
   −1                                     59 (34.7)                                                    176 (34.5)           
   −2                                     47 (27.6)                                                    77 (15.1)            
   −3                                     29 (17.1)                                                    40 (7.8)             
   −4                                     13 (7.6)                                                     16 (3.1)             
  Charlson Comorbidity Index              1.3±1.1                                                      1.5±1.5              0.017
  Concomitant asthma                      52 (30.4)                                                    38 (7.4)             \<0.001
  LAMA usage over 360 days                107 (62.6)                                                   70 (13.7)            \<0.001
  Pulmonary function tests                                                                                                  
   FEV~1~, % predicted                    40.2±13.0                                                    54.1±20.0            \<0.001
   FVC, % predicted                       62.8±16.8                                                    71.1±19.1            \<0.001
   FEV~1~/FVC ratio, %                    47.6±10.8                                                    54.9±11.0            \<0.001
   DLco, % predicted                      61.4±23.1                                                    70.1±20.7            0.003
   Respiratory admission within 2 years   25 (14.6)                                                    52 (10.2)            0.110
   X-ray severity (0--6)                  3.3±1.4                                                      2.9±1.3              \<0.001
   Long-term oxygen therapy               31 (18.1)                                                    28 (5.5)             \<0.001

**Notes:** Data are presented as mean ± standard deviation or number of patients (%), unless otherwise indicated.

ICS/LABA group included patients who were prescribed the fluticasone propionate/salmeterol or budesonide/formoterol inhaler for ≥360 days during the follow-up period.

**Abbreviations:** DLco, diffusing capacity for carbon monoxide; LAMA, long-acting muscarinic antagonist; ICS/LABA, inhaled corticosteroid/long-acting beta-2 agonist.

###### 

Risk factors for mortality in tuberculous destroyed lung patients with airflow limitation

                                   Univariate analysis   Multivariate analysis                                    
  -------------------------------- --------------------- ----------------------- --------- ------- -------------- ---------
  Age, years                       1.047                 1.023--1.071            \<0.001   1.059   1.032--1.087   \<0.001
  Male gender compared to female   1.979                 1.104--3.547            0.022     1.239   0.576--2.666   0.583
  Body mass index                  0.876                 0.813--0.943            \<0.001   0.892   0.826--0.964   0.004
  Ever smoker                      1.509                 0.926--2.460            0.099     1.024   0.543--1.933   0.941
  mMRC dyspnea scale                                                             0.326                            
  0 (reference)                    1.000                                                                          
   1                               0.805                 0.448--1.446            0.805                            
   2                               0.973                 0.486--1.948            0.973                            
   3                               1.274                 0.609--2.666            0.520                            
   4                               2.201                 0.836--5.793            0.110                            
  Charlson Comorbidity Index       1.553                 1.374--1.756            \<0.001   1.495   1.315--1.700   \<0.001
  Concomitant asthma               0.654                 0.313--1.364            0.257                            
  LAMA usage                       0.609                 0.326--1.135            0.118     0.405   0.211--0.776   0.006
  ICS/LABA usage                   0.951                 0.568--1.592            0.848                            
  FEV~1~, % predicted              0.984                 0.971--0.997            0.015     0.985   0.970--1.001   0.062
  X-ray severity (0--6)            1.329                 1.120--1.578            0.001     1.244   1.004--1.541   0.045
  Long-term oxygen therapy         2.146                 1.176--3.916            0.013     1.301   0.686--2.466   0.420

**Note:** Cox proportional hazards analysis was performed.

**Abbreviations:** DLco, diffusing capacity for carbon monoxide; LAMA, long-acting muscarinic antagonist; ICS/LABA, inhaled corticosteroid/long-acting beta-2 agonist.

###### 

Baseline characteristics of patients in LAMA and non-LAMA groups after propensity score matching

                                          Including patients with ICS/LABA usage   Excluding patients with ICS/LABA usage                                                       
  --------------------------------------- ---------------------------------------- ---------------------------------------- --------- ------- ----------- ----------- --------- -------
  Number of patients                                                                                                                                                            
  Age (years)                             63.6±10.4                                62.4±10.1                                0.364     0.117   64.2±9.6    64.7±10.0   0.766     0.053
  Male gender                             90 (74.4)                                87 (71.9)                                0.772     0.056   50 (78.1)   51 (79.7)   \>0.999   0.038
  Body mass index (kg/m^2^)               21.7±3.4                                 21.6±3.4                                 0.794     0.034   21.2±3.2    20.6±3.5    0.297     0.185
  Ever smoker                             78 (64.5)                                76 (62.8)                                0.894     0.034   42 (65.6)   45 (70.3)   0.705     0.101
  mMRC dyspnea scale                                                                                                        0.778     0.172                           0.903     0.182
   −0                                     23 (19.0)                                24 (19.8)                                                  15 (23.4)   16 (25.0)             
   −1                                     42 (34.7)                                49 (40.5)                                                  25 (39.1)   28 (43.8)             
   −2                                     34 (28.1)                                32 (26.5)                                                  17 (26.6)   13 (20.3)             
   −3                                     15 (12.4)                                12 (9.9)                                                   5 (7.8)     4 (6.3)               
   −4                                     7 (5.8)                                  4 (3.3)                                                    2 (3.1)     3 (4.7)               
  Charlson Comorbidity Index              1.4±1.1                                  1.5±1.4                                  0.796     0.033   1.5±1.2     1.4±1.2     0.829     0.038
  Concomitant asthma                      24 (19.8)                                22 (18.2)                                0.870     0.042   5 (7.8)     3 (4.7)     0.715     0.129
  ICS/LABA usage over 360 days            53 (43.8)                                54 (44.6)                                \>0.999   0.017   0           0                     
  Pulmonary function tests                                                                                                                                                      
   FEV~1~, % predicted                    42.9±13.6                                43.5±14.8                                0.776     0.037   45.4±14.6   45.1±15.1   0.906     0.021
   FVC, % predicted                       63.9±16.0                                65.2±18.6                                0.556     0.076   64.5±16.4   63.8±18.3   0.823     0.040
   FEV~1~/FVC ratio, %                    49.8±11.0                                48.8±10.7                                0.478     0.091   52.2±11.1   51.8±10.8   0.822     0.040
   DLco, % predicted                      60.8±23.0                                66.7±20.3                                0.192     0.098   59.2±20.6   63.4±22.0   0.464     0.159
   Respiratory admission within 2 years   15 (12.4)                                12 (9.9)                                 0.683     0.079   7 (10.9)    8 (12.5)    \>0.999   0.049
   X-ray severity (0--6)                  3.2±1.3                                  3.2±1.4                                  0.732     0.044   3.2±1.2     3.0±1.2     0.374     0.158
   Long-term oxygen therapy               16 (13.2)                                12 (9.9)                                 0.547     0.103   6 (9.4)     6 (9.4)     \>0.999   0

**Note:** Data are presented as mean ± standard deviation or number of patients (%), unless otherwise indicated.

**Abbreviations:** DLco, diffusing capacity for carbon monoxide; ICS/LABA, inhaled corticosteroid/long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist; SMD, standardized mean differences.

[^1]: These authors contributed equally to this work
